STK38 is a critical upstream regulator of MYC’s oncogenic activity in human B-cell lymphoma

The MYC protooncogene is associated with the pathogenesis of most human neoplasia. Conversely, its experimental inactivation elicits oncogene addiction. Besides constituting a formidable therapeutic target, MYC also has an essential function in normal physiology, thus creating the need for context-specific targeting strategies. The analysis of post-translational MYC activity modulation yields novel targets for MYC inactivation. Specifically, following regulatory network analysis in human B-cells, we identify a novel role of the STK38 kinase as a regulator of MYC activity and a candidate target for abrogating tumorigenesis in MYC-addicted lymphoma. We found that STK38 regulates MYC protein stability and turnover in a kinase activity-dependent manner. STK38 kinase inactivation abrogates apoptosis following B-cell receptor activation, whereas its silencing significantly decreases MYC levels and increases apoptosis. Moreover, STK38 knockdown suppresses growth of MYC-addicted tumors in vivo, thus providing a novel viable target for treating these malignancies.

[1]  Lawrence H. Schwartz,et al.  Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation , 2011, Science Translational Medicine.

[2]  M. Eilers,et al.  Control of cell proliferation by Myc. , 1998, Trends in cell biology.

[3]  P. Silver,et al.  Human Mob Proteins Regulate the NDR1 and NDR2 Serine-Threonine Kinases* , 2004, Journal of Biological Chemistry.

[4]  C. Heizmann,et al.  Calcium regulation of Ndr protein kinase mediated by S100 calcium‐binding proteins , 1998, The EMBO journal.

[5]  B. Hemmings,et al.  The human tumour suppressor LATS1 is activated by human MOB1 at the membrane. , 2006, Biochemical and biophysical research communications.

[6]  Dean W. Felsher,et al.  Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation , 2007, Proceedings of the National Academy of Sciences.

[7]  B. Hemmings,et al.  Ndr Protein Kinase Is Regulated by Phosphorylation on Two Conserved Sequence Motifs* , 1999, The Journal of Biological Chemistry.

[8]  J. Barrett,et al.  An amino-terminal c-myc domain required for neoplastic transformation activates transcription , 1990, Molecular and cellular biology.

[9]  C. Prives,et al.  Susceptibility of p53 Unstructured N Terminus to 20 S Proteasomal Degradation Programs the Stress Response*♦ , 2009, The Journal of Biological Chemistry.

[10]  S. R. Hann.  Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. , 2006, Seminars in cancer biology.

[11]  D. Engelberg.  Stress-activated protein kinases-tumor suppressors or tumor initiators? , 2004, Seminars in cancer biology.

[12]  A. Harris,et al.  Analysis of gene expression in ductal carcinoma in situ of the breast. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  Stephen K. Burley,et al.  X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors , 2003, Cell.

[14]  J. Kaptein,et al.  Anti-IgM-mediated Regulation of c-myc and Its Possible Relationship to Apoptosis* , 1996, The Journal of Biological Chemistry.

[15]  A. Whitmarsh,et al.  Docking Interactions in the c-Jun N-terminal Kinase Pathway* , 2004, Journal of Biological Chemistry.

[16]  Brian A. Hemmings,et al.  NDR Kinase Is Activated by RASSF1A/MST1 in Response to Fas Receptor Stimulation and Promotes Apoptosis , 2008, Current Biology.

[17]  S. Kim,et al.  Multiple cell-type-specific elements regulate Myc protein stability , 2004, Oncogene.

[18]  C. Heizmann,et al.  Structure of the Ca2+/S100B/NDR kinase peptide complex: insights into S100 target specificity and activation of the kinase. , 2003, Biochemistry.

[19]  M. Gilman,et al.  Proteasome‐mediated degradation of transcriptional activators correlates with activation domain potency in vivo , 1999, The EMBO journal.

[20]  G. Prendergast,et al.  New Myc-interacting proteins: a second Myc network emerges , 1999, Oncogene.

[21]  S. Lowe,et al.  A conserved element in Myc that negatively regulates its proapoptotic activity , 2005, EMBO reports.

[22]  Colin J. Daniel,et al.  The Axin1 scaffold protein promotes formation of a degradation complex for c‐Myc , 2009, The EMBO journal.

[23]  Y. Hosoi,et al.  Negative regulation of MEKK1/2 signaling by Serine-Threonine kinase 38 (STK38) , 2008, Oncogene.

[24]  Andrea Califano,et al.  Genome-wide dissection of posttranscriptional and posttranslational interactions. , 2012, Methods in molecular biology.

[25]  Kai Wang,et al.  Dissecting the Interface Between Signaling and Transcriptional Regulation in Human B Cells , 2008, Pacific Symposium on Biocomputing.

[26]  E. Nigg,et al.  Centrosome-associated NDR kinase regulates centrosome duplication. , 2007, Molecular cell.

[27]  Huajian Gao,et al.  A microarray-based gastric carcinoma prewarning system. , 2005, World journal of gastroenterology.

[28]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[29]  H. Rogniaux,et al.  Mechanism of Ca2+-mediated Regulation of NDR Protein Kinase through Autophosphorylation and Phosphorylation by an Upstream Kinase* , 2003, The Journal of Biological Chemistry.

[30]  D. Felsher,et al.  Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. , 2003, Blood.

[31]  D. Felsher.  Oncogenes as therapeutic targets. , 2004, Seminars in cancer biology.

[32]  Y. Shaul,et al.  The nanny model for IDPs. , 2009, Nature chemical biology.

[33]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  L. Genestier,et al.  Apoptosis induced by polyclonal antilymphocyte globulins in human B-cell lines. , 1994, Blood.

[35]  S. Kim,et al.  Skp2 regulates Myc protein stability and activity. , 2003, Molecular cell.

[36]  B. Hemmings,et al.  Downstream of human NDR kinases: Impacting on c-myc and p21 protein stability to control cell cycle progression , 2011, Cell cycle.

[37]  D. Felsher,et al.  Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.

[38]  A. Patel,et al.  myc function and regulation. , 1992, Annual review of biochemistry.

[39]  R. Dalla‐Favera,et al.  Direct activation of TERT transcription by c-MYC , 1999, Nature Genetics.

[40]  Ariele Viacava Follis,et al.  Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. , 2008, Chemistry & biology.

[41]  D. Felsher.  Reversibility of oncogene-induced cancer. , 2004, Current opinion in genetics & development.

[42]  B. Hemmings,et al.  Human NDR Kinases Control G1/S Cell Cycle Transition by Directly Regulating p21 Stability , 2011, Molecular and Cellular Biology.

[43]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[44]  W. Gu,et al.  Non-transcriptional control of DNA replication by c-Myc , 2007, Nature.

[45]  Jörg Gsponer,et al.  Intrinsically disordered proteins: regulation and disease. , 2011, Current opinion in structural biology.

[46]  J. S. Sodhi,et al.  Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. , 2004, Journal of molecular biology.

[47]  Mariano J. Alvarez,et al.  Genome-wide Identification of Post-translational Modulators of Transcription Factor Activity in Human B-Cells , 2009, Nature Biotechnology.

[48]  H. Weintraub,et al.  Sequence-specific DNA binding by the c-Myc protein. , 1990, Science.

[49]  Adam A. Margolin,et al.  Reverse engineering of regulatory networks in human B cells , 2005, Nature Genetics.

[50]  B. Hemmings,et al.  Molecular cloning and characterization of a conserved nuclear serine(threonine) protein kinase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[51]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[52]  Kathryn A. O’Donnell,et al.  An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets , 2003, Genome Biology.